Prof. Eldad Zacksenhaus

University Health Network, Canada

Email: eldad.zacksenhaus@utoronto.ca

Qualifications

1990 Ph.D., University of Toronto, microbiology

1980 B.Sc., Tel-Aviv University, chemistry

Publications (selected)

1. Jiang Z., Jones R., Deng T., Li H., Herschkowitz J.I., Liu J.C., Weigman V.J., Tsao M.-S., Lane T.F., C.M. Perou, and Zacksenhaus E. Rb deletion in mouse mammary progenitors induces luminal-B or basal-like/EMT tumor subtypes depending on p53 status. Journal of Clinical Investigation. (2010) 120(9):3296-309.
2. Bremner R. and Zacksenhaus E. Cyclins, Cdks, E2f, Skp2 and More at the First International RB Tumor Suppressor Meeting. (2010) Cancer Res. 70(15):6114–6118.
3. Ciavarra G and Zacksenhaus E. Rescue of myogenic defects in Rb-deficient cells by inhibition of autophagy or by hypoxia-induced glycolytic shift. J. Cell Biol. (2010) 191(2):291–301.
4. Ciavarra G., Ho A.T, Cobrinik D., and Zacksenhaus E. Critical role of the Rb family in myoblast survival and fusion. PLoS One. (2011) 6(3):e17682.
5. Ciavarra G. and Zacksenhaus E. Direct and indirect effects of the pRb tumor suppressor on Autophagy. Autophagy. (2011) 7(5):544–546.
6. Jiang Z., Jones R., Liu J.C., Deng T., Robinson T., Chung P.E.D., Wang S., Herschkowitz J.I., Egan S.E., Perou C.M., and Zacksenhaus E. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle. (2011) 10(10):1563–1570.
7. Ciavarra G. and Zacksenhaus E. Multiple pathways counteract cell death induced by Rb1 loss: Implications for cancer. Cell Cycle. (2011) 10(10):1533–1539.
8. Liu J.C., Voisin V., Badar G.D., Deng T., Pusztai L., Symmans W.F., Esteva F.J., Egan S.E., and Zacksenhaus E. Seventeen-gene Signature from Enriched Her2/Neu Mammary Tumor-Initiating Cells Predicts Clinical Outcome for Human HER2⁺:ERa^- Breast Cancer. Proc. Natl. Acad. Sci. U S A. (2012) 109(15):5832–5837.
9. Robinson TJ, Liu JC, Vizeacoumar F, Sun T, Egan SE, Schimmer A, Datti A, and Zacksenhaus E. RB1 status in triple negative breast cancer cells dictates response to radiation treatment and selective therapeutic drugs. PLoS One. 2013 Nov 12;8(11):e78641.
10. Liu JC, Egan SE, and Zacksenhaus E. A tumor initiating cell-derived prognostic signature for HER2+:ERα- breast cancer; rationale, new features, controversies and future directions. Oncotarget. 2013 Aug;4(8):1317-28.
11. Robinson TJ, Pai M, Liu JC, Vizeacoumar F, Sun T, Egan SE, Datti A, Huang J, and Zacksenhaus E. High-throughput screen identifies disulfiram as a potential therapeutic for triple-negative breast cancer cells: interaction with IQ motif-containing factors. Cell Cycle, 2013 Sep 15;12(18):3013-24.
12. Deng T, Liu JC, Chung PE, Uehling D, Aman A, Joseph B, Ketela T, Jiang Z, Schachter NF, Rottapel R, Egan SE, Al-Awar R, Moffat J, Zacksenhaus E. shRNA kinome screen identifies TBK1 as a therapeutic target for HER2+ breast cancer. Cancer Res. 2014 Jan 31. [Epub ahead of print]
13. Jiang Z, Liu JC, Chung P, Egan SE, Zacksenhaus E. Targeting HER2+ breast cancer: The TBK1/IKKe axis. Invited Perspective - Oncoscience.. 2014 Mar 6;1(2):180-2.
14. Liu JC, Voisin V, Wang S, Lehal R, Wang D-Y, Datti A, Uehling D, Al-awar R, Egan SE, Bader GD, Tsao M, Mak TW, Zacksenhaus E. Combined deletion of murine Pten and p53 induces mammary tumors with dependency on eEF2K. EMBO Molecular Medicine. 2014 Oct 20;6(12):1542-60.